Healthcare & Life Sciences
BYoRNA
France
pre-seed
pre-seed
Stage
1
Investors
About
BYoRNA develops a platform for industrial in vivo production of clinical-grade messenger RNA (mRNA) for human and animal health applications, including vaccines and therapies targeting infectiology, oncology, and rare diseases.
Explore BYoRNA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.